New Zealand Pharmaceuticals
Archer Capital completed the acquisition of New Zealand Pharmaceuticals (NZP) in March 2016. NZP is a leading developer and manufacturer of biopharmaceutical products including high purity bile acids, specialised blood group products, complex carbohydrates and other pharmaceutical intermediates. Established in 1971, NZP has evolved to become a valued supplier to leading global pharmaceutical product manufacturers across Asia, Europe and North America.
NZP is based in Palmerston North, New Zealand and is the world’s second largest manufacturer of cholic acid; the key ingredient in the formulation of UDCA which is used to treat a range of liver related conditions. NZP also has a presence in the UK through its Dextra Laboratories division that specialises in the development and production of blood group products, and also leads the Group’s R&D programme. NZP employs around 150 people of which 30 are PhD qualified scientists.